Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer

Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer

Dec 06, 2017
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-kisqali-first-and-only-cdk46-inhibitor-show-superior-median-pfs-compared-oral-endocrine-therapy-first-line-treatment-prospective-randomized-phase-iii-trial-dedicated-premenopausal-women-hrher2-advanced-breast-cancer-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-kisqali-first-and-only-cdk46-inhibitor-show-superior-median-pfs-compared-oral-endocrine-therapy-first-line-treatment-prospective-randomized-phase-iii-trial-dedicated-premenopausal-women-hrher2-advanced-breast-cancer-0